Erowid
 
 
Plants - Drugs Mind - Spirit Freedom - Law Arts - Culture Library  
Take a Survey on the use of Breathwork
for Anxiety, Depression, Trauma, or PTSD
Researchers at Johns Hopkins seek responses to an anonymous survey on breathwork. You can participate whether your breathwork experiences helped or not.
(Must be 18+) Take the Survey!
DEA Federal Register Entry
U.S. Federal register
Date="06/29/93" Citation="58 FR 34708" Group="legal" Type="RULE" Department="DEPARTMENT OF JUSTICE" Agency="DRUG ENFORCEMENT ADMINISTRATION, DEPARTMENT OF JUSTICE" Subject="Schedules of Controlled Substances: Exempt Anabolic Steroid Products"
------------------------------------------------------------ 21 CFR Part 1308 Schedules of Controlled Substances: Exempt Anabolic Steroid Products AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final rule.
------------------------------------------------------------ 21 CFR Part 1308 Schedules of Controlled Substances: Exempt Anabolic Steroid Products AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final rule. + ------------------------------------------------------------ SUMMARY: The interim rule (58 FR 16772, March 31, 1993) which identified five anabolic steroid products as being exempt from certain regulatory provisions of the Controlled Substances Act (CSA) (21 U.S.C. 801 et seq.) is adopted without change. EFFECTIVE DATE: June 29, 1993. FOR FURTHER INFORMATION CONTACT: Howard McClain, Jr., (Chief, Drug and Chemical Evaluation Section), 202-307-7183. SUPPLEMENTARY INFORMATION: The Director, Office of Diversion Control, Drug Enforcement Administration (DEA), published in the Federal Register, an interim rule which identified five products as being exempt anabolic steroid products (58 FR 16772, March 31, 1993). Comments were requested, none were received. The interim rule is adopted without change. The listing of products in 21 CFR 1308.34 relieves persons who handle them in the course of legitimate business from the registration, records, reports, prescription, physical security, import, and export requirements associated with Schedule III controlled substances. Accordingly, the Director certifies that this action will have no impact on the ability of small businesses to compete and he therefore determines that no regulatory flexibility analysis is required. This action has been analyzed in accordance with the principles and criteria in E.O. 12612, and it has been determined that this matter does not have sufficient federalism implications to require the preparation of a Federalism Assessment. It has been determined that drug control matters are not subject to review by the Office of Management and Budget (OMB) pursuant to the provisions of E.O. 12291. Accordingly, this action is not subject to those provisions of E.O. 12778 which are contingent upon review by OMB. Nevertheless, the Director has determined that this is not a "major rule,'' as that term is used in E.O. 12291, and that it would otherwise meet the applicable standards of sections 2 (a) and 2(b)(2) of E.O. 12778. List of Subjects in 21 CFR Part 1308 Administrative practice and procedure, Drug traffic control, Narcotics, Prescription drugs. Under the authority vested in the Attorney General by title XIX of Public Law 101-647, as delegated to the Administrator of the DEA pursuant to 21 U.S.C. 871(a) and 28 CFR 0.100, the Director of the Office of Diversion Control hereby adopts as a final rule, without change, the interim rule amending 21 CFR 1308.34 which was published at 58 FR 16772 on March 31, 1993. Dated: June 22, 1993. Gene R. Haislip, Director, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 93-15180 Filed 6-28-93; 8:45 am] BILLING CODE 4410-09-M
.